Hummingbird Bioscience Announces Poster Presentation on HMBD-802, Novel Dual-Payload Antibody-Drug Conjugate, at EORTC-NCI-AACR 2024 Hummingbird Bioscience today announced a poster presentation on HMBD-802, a dual-payload ADC, at the 36th EORTC-NCI-AACR symposium.

Hummingbird Bioscience Announces Key Leadership Appointments Hummingbird Bioscience Announces Key Leadership Appointments • Kon Yew Kwek appointed Chief Medical Officer • Lisa Ooi appointed Chief Operating Officer

Hummingbird Bioscience Presents New Preclinical Data Highlighting Next-Generation Antibody-Drug Conjugate Capabilities at PEGS Boston 2024 Hummingbird Bioscience will present next-generation antibody-drug conjugate capabilities at PEGS Boston 2024 for the first time.